Trial Profile
A Phase I Trial Evaluating the Safety and Efficacy of Vorinostat (Zolinza) + RVD (Lenalidomide [Revlimid] + Bortezomib [Velcade] + Dexamethasone) for Patients With Newly Diagnosed Multiple Myeloma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Bortezomib (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary) ; Vorinostat (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- 01 Nov 2021 Status changed from active, no longer recruiting to completed.
- 30 Mar 2021 Planned End Date changed from 1 Feb 2021 to 20 Oct 2021.
- 30 Mar 2021 Planned primary completion date changed from 1 Feb 2021 to 20 Oct 2021.